NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Jul 1, 2026 → Nov 1, 2028
NCT ID
NCT07441200About NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo
NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo is a phase 2 stage product being developed by Nippon Shinyaku for Pulmonary Arterial Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07441200. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07441200 | Phase 2 | Recruiting |
Competing Products
20 competing products in Pulmonary Arterial Hypertension